The Cancer Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
The market for cancer
treatments is one of the largest and fastest growing areas in
the pharma industry. Most innovation in oncology over the past
10 years has been driven by scientific advances, particularly in
the genomics, transcriptomics and proteomics sciences.
Successful oncology players of the future will be those that can
anticipate protocol evolution and design the most relevant
clinical trials. More recently, biotech companies have been
driving innovation in oncology more than ever before. Partnering
with biotech companies is an important but expensive source of
innovation for many pharma companies, with approximately 75% of
phase II, III and pre-registration innovative drugs are of
ĎThe Cancer Market Outlook to 2013í is a new report published by
Business Insights that provides comprehensive coverage of the
major markets in the global cancer area, incorporating a
detailed epidemiological analysis of the nine major indications
and key factors impacting their prevalence. Current leading
brands of treatment within each cancer indication are analysed
and eight of the marketís leading players are profiled. With
coverage of over 90% of the total market for cancer products,
this report profiles the factors and underlying trends that are
driving market transformation and identifies the most promising
areas of potential growth. Forecasts for currently marketed and
key pipeline products over the 2007-13 period are also provided.
Discover the key market trends and growth drivers of the cancer
market, assess the competitive dynamics of leading pharma
companies and evaluate the future prospects of major products
with this report...
Assess leading brands of treatment for each indication, identify
potential growth opportunities and compare the outlooks of
leading companies within the cancer market with this new
Some key findings from this report...
- Antineoplastic mAbs accrued sales of $11.3bn in 2007, amassing
a market share of 34.1%. The most prominent contributors to
market share in this class were MabThera (32.8%), Herceptin
(28.8%), Avastin (25.2%) and Erbitux (10.2%). The total
antineoplastics market is forecast to be valued at $43.0bn in
- Amgenís blockbuster brands Neulasta (pegfilgrastim) and
Neupogen (filgrastim) dominated the immunostimulant market in
2007, with sales of $3.5bn and $1.4bn respectively. Forecast
sales for the immunostimulants market are estimated to reach
$17.6bn in 2013.
- Roche is the leader in the global market for cancer
treatments, with a market share of 34.9% (equivalent to $13bn
sales) in 2007. Roche has recently bolstered its position
through portfolio expansion, with the purchase of majority
stakes in both Genentech and Chugai.
- A definitive merger between Eli Lilly and ImClone will
increase Eli Lillyís flow of high-quality, innovative therapies.
This will enable the company to offer physicians/patients a
complementary portfolio of leading agents/targeted therapies
including Gemzar, Alimta & Erbitux.
- Pfizer has a robust R&D pipeline with eight molecules in phase
II and thirteen molecules in phase I, the highest among all the
top ten companies in global cancer market.
Top five reasons to order your copy today
- Assess patient potential, treatment trends and sales patterns
of major cancer indications over the period 2007-13, with this
reportís coverage of lung, breast, colorectal, ovarian cancer
markets across Japan, France, Germany, Italy, Spain, the UK and
- Measure the market performance and strategic positioning of
major pharmaceutical corporations with this reportís evaluation
of the franchises and market shares of Roche, Amgen, Sanofi-Aventis,
Merck KgaA, Novartis, Pfizer, Schering-Plough and Eli Lilly.
- Discover the market dynamics of the cancer area and understand
the impact of recent key events by assessing major market
trends, growth drivers and the latest issues affecting product
- Compare the cancer pipeline compounds of leading companies
with this reportís detailed analysis of clinically
differentiated pipeline products by indication, in addition to
sales forecasts for key R&D pipeline products in the global
cancer market to 2013.
- Understand which indications are likely to generate franchise
growth and examine major classes of cancer treatments including antineoplastics, immunostimulants and cytotoxic hormone
Key issues examined in this report...
- Reimbursement for cryoablation treatments. The new 2008 CMS
rates for prostate cryoablation (in outpatient hospitals), under
APC code 674, were raised from $6,685 to $7,816, an increase of
16.9%. The cryoablation rates for ambulatory surgical centers,
known as ASC code 55873, were raised from $1,339 to $6,219, an
increase of 364%.
- Plant-based cancer vaccine. Researchers are developing a plantbased vaccine which can be created more quickly and at far
less expense than the animal-based version. The antibodies
produced may also trigger a stronger immune response than in
- Novel inhibitor of human microRNA. The Wistar Institute team
have identified a small molecule that blocks the pathway of
miR-21, which is implicated in brain cancer, as well as lung,
colon, breast, and ovarian cancer. With further development, the
molecule has the potential to boost patient response to existing
- NICE guidance on kidney cancer drugs. The availability of high
cost cancer drugs is one of the most pressing issues for the
NHS. Drug makers are developing proposals which may reduce
future drug costs.
Your questions answered...
- Which indications will experience the greatest growth in the
global cancer market over the period 2008-13?
- How have recent major product launches from companies such as
Roche, Amgen, Pfizer and Merck KGaA performed?
- What is the forecast market potential of the most exciting
compounds currently in development for cancer indications?
- Which companies are best positioned for future success?
- What is the forecast market size and growth rate over the
period 2007-2013 across the major cancer indications?
- How will generic competition influence the future of branded
products and which defensive strategies provide the most
- Which pipeline products offer the highest growth potential?
- What will be the competitive landscape of lung, breast,
colorectal, ovarian, prostate, lymphoma and pancreatic cancer in
Table Of Contents >